Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review

Carles Moliner-Abós, Mercedes Rivas-Lasarte, Julia Pamies Besora, Paula Fluvià-Brugues, Eduard Solé-González, Sonia Mirabet, Laura López López, Vicens Brossa, Maria José Pirla, Nuria Mesado, Jesús Álvarez-García, Eulàlia Roig

Research output: Contribution to journalArticlepeer-review

25 Scopus citations


Purpose: Sacubitril/valsartan reduced heart failure (HF) admissions and cardiovascular mortality in the PARADIGM-HF trial. However, real-life studies are scarce comparing daily practice patients with those of the trial. The aim of our study was to analyze the efficacy and safety of the drug in an advanced heart failure cohort and to review systematically the previous real-life studies published to date. Methods: We performed a retrospective analysis of consecutive patients prescribed sacubitril/valsartan in a single tertiary HF clinic between September 2016 and February 2018. HF admissions before and after the initiation of the drug were assessed in a paired fashion. A systematic review of real-life studies published to date was also conducted. Results: Sacubitril/valsartan was started in 108 patients who were in a more advanced NYHA class and more frequently treated with mineral receptor antagonists, internal cardiac defibrillator, and cardiac resynchronization therapy than in the PARADIGM-HF trial. After a 6-month follow-up, we observed a significant reduction in the HF hospitalizations, median levels of NT-proBNP, and need for levosimendan ambulatory perfusion. Likewise, we found a significant improvement in mean LVEF and end diastolic left ventricle diameter. Regarding safety, sacubitril/valsartan was well-tolerated without any severe adverse effect. Conclusion: Sacubitril/valsartan in real-life is prescribed to a more advanced HF population, which could be responsible for the difficulties in reaching high doses of the drug. However, after a 6-month follow-up, sacubitril/valsartan significantly reduces HF hospitalization and induces cardiac reverse remodeling, without remarkable adverse events.

Original languageEnglish
Pages (from-to)307-314
Number of pages8
JournalCardiovascular Drugs and Therapy
Issue number3
StatePublished - 15 Jun 2019
Externally publishedYes


  • Heart failure
  • Real-life practice
  • Review
  • Sacubitril/valsartan


Dive into the research topics of 'Sacubitril/Valsartan in Real-Life Practice: Experience in Patients with Advanced Heart Failure and Systematic Review'. Together they form a unique fingerprint.

Cite this